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Background: Health related quality of life (HRQL), mood disorders and coping abilities have
previously not been evaluated in an unselected sample of patients with primary lung cancer.
Design: A prospective study was performed on all patients diagnosed with primary lung cancer
in Southern Norway from 2002 to 2005. HRQL was assessed according to EORTC, anxiety and
depression according to HAD and coping ability according to SoC.
Results: Fatigue and sore mouth were more pronounced in SCLC than in NSCLC. Besides this,
there were no difference in EORTC scores between histological groups. Non-responders to
EORTC were older and more than twice as many had poor performance status compared to
those answering. According to HAD, 17% of patients scored compatible with anxiety and 14%
with depression, and one in four consistent with manifest anxiety and/or depression. Mean
SoC score was 58.3. A HAD score compatible with anxiety or depression was associated with
considerably worse EORTC function scores. A reduced coping ability according to SoC was only
weakly associated with anxiety and depression. These scores are poorer than that recorded in
selected EORTC databases from chemotherapy and radiotherapy studies.
Conclusion: In this real-life survey on unselected patients with newly diagnosed lung cancer,
mean HRQL scores were poorer than reference values from previous, treatment-based studies,
documenting a higher burden of illness in lung cancer than previously documented. Anxiety
and depression are common in lung cancer and are clearly related to reduced quality of life.
From the clinical point of view, an increased focus on information when lung cancer is diag-
nosed, seems justified, as well as specific attention for patients with lung cancer with accom-
panying mood disorders.
ª 2008 Elsevier Ltd. All rights reserved.8073332/300; fax: þ47 38073327.
o (H.B. Rolke).
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Lung cancer is the most lethal of cancers for both genders
in the western world today, and the incidence still in-
creases. Treatment, though offered more frequently today
than 20 years ago, has not improved the five-year survival
noticeably. However, palliative treatment regimes have
become less toxic, thereby improving quality of life during
treatment. Thus, health related quality of life (HRQL) has
become increasingly more important as an end point in lung
cancer research. Recent investigations also emphasize the
importance of mood aspects in cancer research.1,2
People’s life experiences influence their perception of
illness and symptoms, as well as their susceptibility to
information. Thus, coping ability may explain some vari-
ability in patients’ perception of given information and
actual symptoms.3 Coping ability is thought to be a rather
stable trait, and to be acquired early in life.4 Antonovsky
defines coping ability/sense of coherence as: ‘‘a global ori-
entation that expresses the extent to which one has a per-
vasive, enduring though dynamic feeling of confidence that
the stimuli deriving from one’s internal and external envi-
ronments in the course of living are structured, predict-
able, and explicable’’.4
Significant correlations have previously been found
between HRQL and mood disorders following surgery for
lung cancer, using a generic measure of Quality of life
(HRQL), the SF36,5 and the Hospital Anxiety and Depression
Scale (HAD). Further, Henoch et al. recently reported a cor-
relation between HRQL and both depression and coping
abilities in patients with lung cancer in a purely palliative
setting.1
Thus, the aims of this study were (i) to assess HRQL,
anxiety and depression and coping abilities in an unselected
population of patients with newly diagnosed primary lung
cancer, (ii) to characterize responders and non-responders
to these questionnaires, (iii) to test possible associations
between HRQL, HAD and coping abilities and (iv) to
compare our results with previous studies.
Method
This prospective study included all patients diagnosed with
primary lung cancer in Southern Norway, i.e., the Aust-
Agder and Vest-Agder counties, between June 14th 2002
and June 13th 2005.
There are two main hospitals in Southern Norway serving
all patients with pulmonary carcinoma and together offer-
ing all regular treatment modalities. When the patients
were informed about their disease, the physicians also
invited them to participate in the study, and if willing,
written informed consents were collected and question-
naires answered immediately or mailed to the patient, i.e.
(i) a health related quality of life (HRQL) questionnaire;
The European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire Core
30 (EORTC QLQ-C30) and its Lung Cancer specific
module (QLQ LC13),
(ii) a questionnaire assessing emotions; the Hospital
Anxiety and Depression Scale (HAD), and(iii) Thirteen questions on coping abilities; the Sense of
Coherence questionnaire (SoC).
EORTC and HAD questionnaires answered more than two
weeks after the date of informed diagnosis were excluded
from baseline assessment. However, SoC questionnaires
answered also somewhat later were included in baseline
data due to the documented stable nature of coping
abilities over time.
The EORTC QLQ-C30 judged to be a valid, reliable and
reproducible instrument,6e9 has been used in many clinical
studies,10,11 contains all important aspects of cancer re-
lated HRQL12 and consists of five functional scales (physi-
cal, role, emotional, cognitive and social) and one global
health and quality of life scale, for which a high score
means a high level of functioning. Additionally, it has three
symptom scales (fatigue, pain and nausea/vomiting) and six
single symptom items (dyspnoea, constipation, diarrhoea,
insomnia, appetite loss and financial difficulties) for which
a high score represents a high degree of symptoms. The
QLQ LC13 measures another 13 disease- and treatment spe-
cific symptoms. The QLQ-C30 and QLQ LC13 answers were,
according to EORTC instructions,13 converted into scales
from 0 to 100. A difference of more than 10 points or 10%
in EORTC scores is often considered clinically significant.14
Single missing answers were imputed according to the
EORTC scoring instructions in cases where at least half
the items of each multi-item scale had been answered. Sin-
gle items could not be supplemented.
The HAD questionnaire consists of 14 items of which half
and half assess anxiety and depression, respectively. Each
sub-score may vary from 0 to 21 points. The questionnaire
has been widely tested.15,16 The scoring instructions for the
HAD-scale suggest that 8 points are equivalent to possi-
ble/borderline psychiatric disease, while 11 points indi-
cate clinical depression or anxiety associated neurosis,16
as reported in several other studies.15,17 Missing values
were, according to the HAD instructions, replaced with
the mean of the other values for anxiety or depression,
rounded off to nearest whole number, if four values or
less were missing.
The SoC questionnaire, as invented by Antonovsky, has
been proved valid and reliable,18 and is widely used through-
out the world,19,20 also in Norway.3 The answers of the 13-
item version were coded as instructed with values from 1
(weak coping ability) to 7 (strong coping ability). Total score
resulted from summing up raw scores, and could range from
13 to 91. High values indicate high coping abilities.
Statistical methods
Statistical descriptive analyses were performed with SPSS
13 (Statistical package for Social Sciences, SPSS Inc.
Chicago, USA). Normally distributed data are presented
with mean and standard deviation (SD) as the measures of
central tendency and dispersion, respectively. Correspond-
ingly, non-normally distributed continuous data are pre-
sented with median and interquartile range (IQR, i.e., 25th
and 75th percentiles), respectively. However, although
many EORTC data present with a skewed distribution,
here they are primarily reported with mean values and
SD, as this is the preferred method in comparable studies.
Eligible 492
Moved 2/
Refused 6/
Did not speak language 1
Included 479
Faulty diagnosis;
Malign.mesothelioma 2/
TBC1/breast cancer 1
Response rate
EORTC
n = 303
63%
HAD
n = 290
61%
SoC
n = 251
52%
Figure 1 Eligible, excluded and included patients with newly
diagnosed primary lung cancer in Southern Norway from 2002
to 2005 and response rate to questionnaires at baseline.
1462 H.B. Rolke et al.Differences in EORTC and HAD scores were compared
between histological groups (Small Cell Lung Cancer (SCLC)
vs. Non-Small Cell Lung Cancer (NSCLC) vs. unknown
histology), Eastern Cooperative Oncology Group Perfor-
mance Status (ECOG PS) 0e2 vs. 3e4,21 Tumour Node Me-
tastasis (TNM) stage a.m. Mountain 1ae3a vs. 3be4.22
Differences were considered statistically significant with
an alpha below 0.05 (p< 0.05), two-sided test.
HAD scores were tested both as continuous scores and
categoricals, the latter with a cut-off at 11 points. Simple
linear regression analyses were performed with EORTC
scores, HAD scores or SoC scores as dependent variables,
and the following categorical variables as explanatory
variables: age (cut-off: <70 yearsZ 0, 70 yearsZ 1),
gender (maleZ 0, femaleZ 1), histology (SCLCZ 0 vs.
NSCLCZ 1), ECOG PS (0e2Z 0, 3e4Z 1), TNM stage
(1ae3aZ 0, 3be4Z 1), and anxiety and depression (score
<11Z 0, 11Z 1). EORTC-variables resulting in significant
p-values, were further tested in multiple linear regression
analyses with backward stepwise conditional methods. Be-
cause of skewed data, Spearman’s rank correlation in steadTable 1 Baseline characteristics in an unselected sample of pa
Norway.
All (nZ 479) NSCLC
(nZ 334)
SCLC
(nZ
Age, years, mean (SD) 67.9 (11) 68.3 (11) 66.9(
Gender, male, % 58 61 51
Never-smokers, % 5 5 4
ECOG, %
0e2 66 66 69
3e4 34 34 31
TNM, %
1ae3a 28 33 11
3be4 72 67 89
SCLC - small cell lung cancer; and NSCLC - non-small cell lung cancer
Values of statistical significance in right column are tested between t
and/or SCLC groups).of simple linear regression and the effects of log-transfor-
mation of EORTC and HAD scores were also tested.
The differences between mean values from present
study and values from selected EORTC databases14 and
the general Norwegian population,23 were tested in Sample
Power, version 2.0, with independent sample t-test, assum-
ing sample sizes equal to the lowest comparable sample
size tested and with actual standard deviations in calcula-
tion where available with an alpha< 0.05, two-sided test
and a power >80%, i.e., beta< 0.20.
Results
Of a total of 492 consecutive patients originally diagnosed
with primary lung cancer, 479 patients were included in the
study, giving an inclusion rate of 97% (Fig. 1).
Two-thirds of all patients were in ECOG status 0e2 at the
time of diagnosis, and more than two-thirds had advanced
cancer, i.e., TNM stage 3be4 (Table 1).
Total of 63, 61 and 52% of the unselected patient
population answered the EORTC, HAD and SoC question-
naires at the time of diagnosis, respectively (Table 2).
Ninety-six percent of those answering EORTC question-
naires also answered the HAD questionnaires. However,
the corresponding correlation between SoC and EORTC/
HAD questionnaires were >84%.
Patients not answering the baseline EORTC question-
naire were older (mean age 7012 vs. 67.0,10 p< 0.002, t-
test), and more than twice as many had poor performance
status (i.e., ECOG 3e4, 59%) compared to those answering
(23%, p< 0.0001, X2, Table 3). Further, there were more
non-responders to EORTC among those suffering from
SCLC with Extensive Disease (54%) compared to those with
Limited Disease (23%, pZ 0.002, X2).
Patients with unknown histology were older, more often
female and in poorer ECOG status andmore advanced tumour
stage than patients with histology as basis for diagnosis.
Differences between groups in EORTC scores 10 points
were evaluated, without revealing any important tenden-
cies. We have thus chosen to focus on statistically signif-
icant differences in this presentation.tients with newly diagnosed primary lung cancer in Southern
102)
p (NSCLC vs.
SCLC)
No histology
(nZ 43)
p (no histology
vs. NSCLC/SCLC)
10) n.s. (t-test) 77.4 (10) <0.0001
n.s. (X2) 47 <0.05
n.s. (X2) 0
n.s. (X2) 21 <0.0001
79 <0.0001
<0.0001 (X2) 30 <0.05
<0.0001 (X2) 70 <0.05
.
he ‘‘no histology’’ group vs. the data in italics to the left (NSCLC
Table 2 Response to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and
Lung Cancer 13 (EORTC QLQ-C30 and LC 13), Hospital Anxiety and Depression Scale (HAD) and Sense of Coherence (SoC)
questionnaires at baseline in an unselected sample of patients with newly diagnosed primary lung cancer in Southern Norway.
Total number
of patients
All (nZ 479) NSCLC
(nZ 334)
SCLC
(nZ 102)
p (NSCLC vs.
SCLC)
No histology
(nZ 43)
p (no histology. vs.
NSCLC/SCLC)
EORTC QLQ-C30þ LC13, mean (SD) (range 0e100) t-test t-test
 Physical function 56.4 (29) 57.4 (29) 56.1 (29) 43.3 (28)
 Role function 41.1 (38) 41.8 (38) 38.3 (39) 41.7 (43)
 Emotional function 70.7 (26) 70.0 (26) 73.2 (25) 70.3 (29)
 Social function 62.1 (34) 62.4 (34) 58.5 (35) 70.8 (27)
 Cognitive function 77.3 (27) 78.4 (27) 74.4 (27) 71.9 (35)
 Overall quality
of life
49.4 (26) 49.0 (26) 49.6 (25) 54.7 (23)
 Fatigue 52.7 (31) 50.2 (31) 61.7 (30) 0.013 55.6 (32)
 Nausea/vomiting 10.1 (20) 9.2 (19) 13.9 (24) 8.3 (15)
 Pain 31.7 (35) 30.5 (35) 35.8 (36) 32.3 (33)
 Dyspnoea 52.3 (34) 51.1 (35) 55.6 (33) 56.3 (36)
 Insomnia 38.8 (37) 37.1 (38) 40.0 (36) 58.3 (31) 0.03
 Appetite loss 35.8 (39) 35.0 (39) 40.6 (39) 29.2 (42)
 Constipation 25.4 (34) 24.1 (34) 26.6 (34) 39.6 (41)
 Diarrhoea 12.1 (22) 11.2 (22) 15.8 (22) 11.1 (21)
 Financial difficulties 7.2 (21) 8.1 (22) 5.2 (20) 2.1 (8)
 Dysphagia 11.4 (26) 10.5 (25) 15.0 (30) 10.4 (26)
 Cough 38.4 (29) 37.3 (30) 43.3 (26) 35.4 (37)
 Dyspnoea lung cancer 39.4 (29) 37.6 (29) 43.2 (27) 50.3 (34)
 Haemoptysis 6.7 (18) 6.7 (18) 7.2 (17) 4.2 (11)
 Sore mouth 9.6 (24) 7.6 (21) 15.6 (31) 0.031 14.6 (30)
 Peripheral neuropathy 13.2 (25) 11.7 (23) 16.4 (30) 22.9 (29)
 Alopecia 5.1 (17) 4.9 (16) 6.1 (20) 4.2 (11)
 Pain in chest 19.4 (28) 19.7 (29) 20.3 (26) 12.5 (24)
 Pain in other places 23.1 (34) 21.1 (33) 28.1 (37) 31.0 (42)
 Pain in arm/shoulder 22.4 (32) 22.9 (33) 16.4 (27) 37.5 (38)
HAD
 Anxiety, % 17 17 17 20
 Depression, % 14 12 22 0.03 (X2) 27
SoC
 Mean (SD), (range 13e91) 58.3 (7) 58.2 (7) 59.4 (8) 56.3 (9)
All non-significant p-values are not printed to increase readability.
SCLC - small cell lung cancer; and NSCLC - non-small cell lung cancer.
Values of statistical significance in right column are tested between the ‘‘no histology’’ group vs. the data in italics to the left (NSCLC
and/or SCLC groups).
Health related quality of life in patients with primary lung cancer 1463According to EORTC, fatigue and sore mouth were more
prevalent in patients with newly diagnosed SCLC compared
to NSCLC (pZ 0.013 and pZ 0.031, respectively). Besides
this, the EORTC, HAD and SoC scores were comparable
between SCLC and NSCLC (Table 2).
Mean EORTC scores were significantly poorer in cases of
reduced performance status (Fig. 2).
Highly significant associations were seen between EORTC
scores and anxiety and depression (Fig. 3). Linear regres-
sion analysis with EORTC as dependent variable, showed
poorer emotional function in cases of anxiety or depression
(all p’s< 0.0001, highest r2Z 0.51), and worse physical and
role functions in cases of poor ECOG performance status
(p’s< 0.0001, highest r2Z 0.22). Some of the other EORTC
parameters showed significant p-values, but insignificant r2(<0.10). Multiple logistic regression analysis showed a four
times increased odds ratio (OR) for depression if ECOG
performance status was 3e4 compared to 0e2, i.e. 30%
had depression in ECOG 3e4 while 10% had depression if
ECOG 0e2 (pZ 0.001). There was a 10 times higher OR
for depression if concurrent anxiety, i.e. 42% of those
with anxiety had depression vs. 8% of patients without
anxiety having depression (p < 0.0001).
Regarding psychiatric disease according to HAD, 17%
and 14% had scores 11, consistent with anxiety and
depression, respectively. Seven percent scored 11 on
both subscales, consistent with combined anxiety and
depression, thus one in four (24%) had scores consistent
with one or more mood disorders (Fig. 4). Ten percent had
anxiety only and seven percent depression only. Thirty-one
Table 3 Characteristics of an unselected population of patients with lung cancer in Southern Norway answering EORTC
questionnaires at baseline compared with those who did not.
EORTC non-
responders
EORTC
responders
p (test)
Age, mean (SD) 69.3 (11) 67.1 (10) 0.031 (t-test)
Sex, female % 45 23 n.s. (X2)
ECOG 3e4, % 53 23 <0.0001 (X2)
SCLC-ED, % 54 23 0.002 (X2)
No histology
vs. all others (NSCLCþ SCLC), %
15 5 <0.0001 (X2)
1464 H.B. Rolke et al.percent showed symptoms qualifying for borderline anxi-
ety, and 27% for borderline depressions (scores 8). There
were no statistically significant differences between
median scores for either anxiety or depression between
genders or histological groups.
Anxious, as well as depressed patients, reported signif-
icantly more fatigue, insomnia, sore mouth, nausea,
dysphagia and financial trouble than non-anxious and non-
depressed patients (all p’s< 0.027). Patients with com-
bined mood disorders reported worse physical (620), role
(620), emotional (641), social (624) and cognitive func-
tion (622), and global HRQL (618) scores, (all p’s< 0.03).
Sense of Coherence scores were normally distributed
and ranged from 34 to 76. There were no differences in SoC
scores between genders, histological groups, ECOG or TNM,
but scores were lower in anxious patients, compared to
non-anxious, i.e., for manifest anxiety (HAD score 11)
55.7 vs. 58.8 (pZ 0.025) and for borderline anxiety (HAD
score 8) 56.3 vs. 59.2 (pZ 0,005), respectively. If depres-
sion scores were 8, mean SoC scores were also signifi-
cantly lower compared to non-depressed, i.e., 55.4 vs.
59.2 (pZ 0.001) and if score 11, 55.2 vs. 58.6
(pZ 0.035), respectively (Fig. 2). In cases of combined
mood disorders, SoC scores were lower, 52.0 vs. 58.6
(pZ 0.006). The SoC scores did not influence the EORTC
scores in simple linear regression analyses, but there was
a significant association between SoC score and EORTC
emotional function and diarrhoea using Spearman’s rank
correlation (p’s< 0.002). SoC scores showed no associations
with ECOG status or with length of education.63,8
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Figure 2 EORTC scores differing significantly between ECOG PS 0e
lung cancer in Southern Norway.When compared with material from EORTC databases,13
reporting data from treatment studies with the inclusion of
patients in good performance status, unselected patients
with newly diagnosed lung cancer report considerably
worse EORTC scores, especially related to role, social and
physical functions as well as global quality of life, and
regarding symptoms related to dyspnoea, diarrhoea and
fatigue (Fig. 5).Discussion
This prospective study on an unselected population of
patients with newly diagnosed lung cancer revealed that
2/3 of patients were in good performance status at the time
of diagnosis, and more than 2/3 had advanced tumour
stage. Fatigue and sore mouth were more pronounced in
small cell lung cancer (SCLC) than in non-small cell lung
cancer (NSCLC). Besides this, there were no differences in
EORTC scores between SCLC and NSCLC.
Mean EORTC scores (physical, role, social, cognitive and
global HRQL functioning scales, fatigue and dyspnoea) were
significantly poorer in cases of reduced performance status
in all patients with lung cancer.
One in four patients with newly diagnosed lung cancer
had scores consistent with manifest anxiety and/or de-
pression. Global HRQL score, as well as function scores and
several symptom scores, proved statistically significantly
worse in patients with HAD scores compatible with anxiety
and/or depression, compared to those without. Further,,7
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Figure 3 Specific baseline EORTC and Sense of Coherence scores in anxious vs. non-anxious and depressed vs. non-depressed
patients in an unselected sample with newly diagnosed primary lung cancer in Southern Norway.
Health related quality of life in patients with primary lung cancer 1465patients with combined mood disorders scored poorer than
those with either anxiety or depression, especially con-
cerning emotional, cognitive and social functions, and
global quality of life, thus emphasizing the association
between mood disorders and HRQL. Patients with anxiety
and depression had a lower Sense of Coherence score, and
there was an increased OR for depression in patients with
poor performance status3,4 or anxiety.
Patients in this real-life study on newly diagnosed
NSCLC scored worse on several function and symptom
scales than in ‘‘reference databases’’ from EORTC-studies,
i.e., patients well enough for inclusion in chemo- or
radiotherapy treatment protocols,13 and not surprisingly
much worse when compared with a randomly chosen,
healthy Norwegian population,23 thus revealing a more
true and heavier burden of illness than in previous studies
in lung cancer.
The major critical comment to this study would be
a low response rate to questionnaires, introducing a con-
siderable possibility of selection bias. However, there are
many reasons for not answering questionnaires in this
context.
(i) First, some were too sick or fatigued to answer.
When handling an unselected sample of patients
with newly diagnosed lung cancer, a higher propor-
tion of patients will be in advanced tumour stage
or reduced ECOG status compared to studiesDepression onlyAnxiety only 17%
A
14%
D
7%
Anxiety and depression
Figure 4 Anxiety, depression and both in an unselected popu-
lation of patients with primary lung cancer in Southern Norway.performed alongside for example chemotherapy
studies, that include mostly patients in ECOG status
0e1 or Karnofsky (60-) 80-100. If only patients in
ECOG 0e1 had been included, the response rate in
this study on HRQL would have been 89%. Further,
the relationship between ECOG status and response
rate is tested to be strong in this study and thus
explains a high proportion of dropouts.
(ii) Second, some felt too shocked to answer question-
naires shortly after being told the diagnosis. Al-
though a general problem in such studies, this
justification evidently must be of greater importance
than in comparable, but highly selected studies, due
to a very high inclusion rate of 97%. Hence, a higher
proportion will, due to emotional reactions, not
answer questionnaires in such unselected materials.
(iii) Third, several patients definitely refused to answer
the SoC questionnaire, as they found the questions
too personal.
(iv) Fourth, for those answering questionnaires by mail,
several patients referred for surgery were not
reached before being hospitalised for surgery. Ques-
tionnaires should according to the protocol be
answered in the current condition, and not
retrospectively.
(v) Eighty-four percent of patients responding to EORTC
and HAD within 14 days of diagnosis, also answered
the SoC. If including later answers in analyses, as
well, response rates would have been better, but
less so reflecting baseline characteristics.
We thus believe the response rates reported in this
study are high standards for an unselected sample of
patients with newly diagnosed lung cancer. However, this
does not reduce the possibility of selection bias. On the
basis of these arguments, our opinion is that the EORTC,
HAD and SoC scores in general most probably would have
been worse than reported here, if a higher proportion of
those with a poor ECOG status also had been able to
answer.
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Figure 5 Health related quality of life scores according to EORTC QLQ-C30 in an unselected sample of patients with newly di-
agnosed non-small cell lung cancer in Southern Norway (CAPPA) compared with a selected material from EORTC databases
(chemotherapy- and radiotherapy studies13) and with a sample from the Norwegian general population.23
1466 H.B. Rolke et al.The EORTC questionnaires are made with the intention
to test changes in patients selected for chemotherapy or
radiation therapy studies. In this study on an unselected
sample of patients with newly diagnosed lung cancer, we
found the EORTC scores to be more skewed and with wider
ranges of scores than in previous treatment studies.24,25
This skewedness is most probably due to the inclusion of
more diseased patients in this material, with more than
two-thirds being in advanced tumour stage at inclusion,
and one-third being in a poor performance status, the latter
being synonymous with exclusion criteria in most modern
treatment studies. Such skewedness puts a further chal-
lenge in the applied statistics used for analyses of data
from unselected materials, like in this study.
Many of the same arguments should explain why the
EORTC scores from this study were poorer than comparable
values from previous EORTC-studies (Fig. 5). Further, more
persons suffered from anxiety and/or depression in this
study compared to another Norwegian study by Aass
et al.,26 a result also indicating the worse status of an un-
selected sample. However, while this study evaluated all
patients with lung cancer during a three-year period, her
study was performed at a specialized cancer clinic, only re-
ceiving patients well enough for specific treatment, and in-
cluding only a small proportion (8%) of patients suffering
from lung cancer.
Regarding the general applicability of these results,
missing a clear trend in scores, and there being no common
score of the EORTC HRQL-questionnaire, makes this ques-
tionnaire less useful to guide clinical evaluations in an
unselected material of patients with lung cancer.
One might argue that depression scores after information
about the serious diagnosis of malignant disease, not neces-
sarily mirror the pre-diagnostic state as precisely as if
measured ahead of information. Pre-diagnostic questioning
was not considered ethical in this study. However, Montazeri
et al.15 found no significant differences in HRQL symptom
scores, using the EORTC questionnaires, between patients
who knew their diagnosis and those who did not, which may
support the validity of our results regarding mood disorders.Compared with results from a nation-wide sample on
2003 randomly selected Swedish inhabitants with mean SoC
score of 65,20 the SoC scores in this study were lower for
both genders. There are few comparable studies on SoC
scores among cancer patients. The most comparable values
are from a study on US minority homeless women, scoring
55.0, indicating that the average patient with SoC score
of 58 is less capable of activating appropriate resources
to cope with serious happenings compared to a healthy
population.18,20 It has been shown that SoC is strongly, in-
versely related to the trait of anxiety.19 Antonovsky4 has
stated that most of the experiences contributing to an indi-
vidual’s mastery or sense of coherence, are collected dur-
ing childhood and early adulthood, and stabilise around
the age of 30. If so, one can hardly claim that a low SoC
score is caused or should be affected by the diagnosis of
cancer. However, Larsson and Kallenberg found that SoC
was more related to general well-being and psychological
factors than to overall physical health and somatic
symptoms.20
One-third of patients in our study scored equal to
borderline anxiety, and one-fourth as borderline depres-
sion. These also had significantly lower SoC scores. Mean-
while, Dalgard et al. have shown that a low level of
education is often associated with a low degree of mastery
and high psychological distress.27 However, our study did
not show different sense of coherence scores in lung cancer
patients with high education compared to low, but statisti-
cal power was low due to few patients with four or more
years of higher education.
Another question is whether people with depression
smoke more than others or tend to start smoking more
frequently than persons without mood disorders, and are
thus over represented in a material of patients with
pulmonary carcinoma, giving a selection bias in such
materials. A topic for future research could be to focus
more on smoking habits in people suffering from mood-
related disorders, as they seem to represent a group with
increased risk for lung cancer, and possibly other tobacco-
associated disorders.
Health related quality of life in patients with primary lung cancer 1467Patients with anxiety or depression were found to have
more symptoms from lung cancer and reduced quality of
life at baseline compared to patients without mood-re-
lated disorders. However, we are not able to comment
from this material whether treatment with anxiolytics or
antidepressants might reduce these perceptions of symp-
toms from lung cancer, and is thus a possible topic for
future research.
Our findings in this real-life study establish the consider-
able burden of illness found in an unselected sample of lung
cancer and may emphasize the necessity for more time
spent on information and follow-up for patients suffering
from mood disorders and a low coping ability in order to
improve their HRQL, thereby possibly reducing their burden
of symptoms.
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